UBS analyst Martin Auster said he is unsure if United Therapeutics' FREEDOM-EV will have a positive outcome. He said United's switch to TID from BID dosing and a longer treatment duration in EV may increase results compared to previous combo trials, but is skeptical whether Orenitram's efficacy will match Uptravi's GRIPHON results. Auster said the firm's expert survey indicates Uptravi has key advantages over Orenitram on perceived efficacy and key metrics such as ease of titration, and side effect/tolerability, but are less likely to be influenced by FREEDOM-EV results, suggesting limited clinical impact from the trial. The analyst rates United Therapeutics a Sell with a $106 price target.